Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efatutazone plus Erlotinib in Advanced NSCLC
NCT01101334Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2010
- Primary completion
- Apr 2013
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of efatutazone in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2010; status: completed.
02
Drugs
efatutazone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01101334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01101334.